Cardiovascular disease risk among breast cancer survivors: an evolutionary concept analysis

References

• CDC. Leading Causes of Death. Atlanta: Center for Disease Control and Prevention; 2013. [updated 2016 October 7]. Available from: http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Accessed July 22, 2016.
   Google Scholar
• Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.
   PubMed Web of Science ®Google Scholar
• Appel JM, Zerahn B, Møller S, et al. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. Acta Oncol. 2012;51(8):1054–1061.
   Web of Science ®Google Scholar
• Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597–8605.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Hussey MA, Moinpour CM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol. 2008;26(8):1223–1230.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Treatment & Survivorship: Facts & Figures 2016−2017. Atlanta, GA: American Cancer Society; 2016.
   Google Scholar
• Surveillance, Epidemiology, and End Results. SEER Stat Fact Sheets: Female Breast Cancer. Maryland: National Cancer Institute. Available from: http://seer.cancer.gov/statfacts/html/breast.html. Accessed July 22, 2016.
   Google Scholar
• Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.
   PubMed Web of Science ®Google Scholar
• Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–635.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Survivorship. Fort Washington, PA: National Comprehensive Cancer Network, Inc.; 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed July 22, 2016.
   Google Scholar
• Bovelli D, Plataniotis G, Roila F; ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v277–v282.
   PubMedGoogle Scholar
• Rodgers BL. 2000. Concept analysis: an evolutionary view. In: Rodgers BL, Knafl KA, editors. Concept Development in Nursing: Foundations, Techniques and Applications. Philadelphia: Saunders; 2000:77–102.
   Google Scholar
• McEwan M, Wills EM. Theoretical Basis for Nursing. 4th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
   Google Scholar
• Boekel NB, Schaapveld M, Gietema JA, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016;94(5):1061–1072.
   PubMed Web of Science ®Google Scholar
• Boerman LM, Berendsen AJ, van der Meer P, Maduro JH, Berger MY, de Bock GH. Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. Support Care Cancer. 2014;22(7):1949–1958.
   Web of Science ®Google Scholar
• Bowles EJ, Wellman R, Feigelson HS, et al; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293–1305.
   PubMedGoogle Scholar
• Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34(10):1122–1130.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–998.
   PubMed Web of Science ®Google Scholar
• Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472.
   PubMed Web of Science ®Google Scholar
• Haque R, Prout M, Geiger AM, et al. Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014;20(1):86–92.
   Web of Science ®Google Scholar
• Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100–4106.
   PubMed Web of Science ®Google Scholar
• Highland KB, Hurtado-de-Mendoza A, Stanton CA, Dash C, Sheppard VB. Risk-reduction opportunities in breast cancer survivors: capitalizing on teachable moments. Support Care Cancer. 2015;23(4):933–941.
   PubMed Web of Science ®Google Scholar
• Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–375.
   PubMedGoogle Scholar
• Jordan JH, Thwin SS, Lash TL, et al. Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat. 2014;146(2):401–409.
   Web of Science ®Google Scholar
• Leung HW, Chan AL, Muo CH. Late cardiac morbidity of adjuvant radiotherapy for early breast cancer – a population-based study. J Cardiol. 2016;67(6):567–571.
   Web of Science ®Google Scholar
• Nichols HB, Trentham-Dietz A, Egan KM, et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1403–1409.
   PubMed Web of Science ®Google Scholar
• Obi N, Gornyk D, Heinz J, et al. Determinants of newly diagnosed comorbidities among breast cancer survivors. J Cancer Surviv. 2014;8(3):384–393.
   Web of Science ®Google Scholar
• Qin A, Thompson CL, Silverman P. Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. J Cancer Surviv. 2015;9(2):252–259.
   PubMed Web of Science ®Google Scholar
• Enright KA, Krzyzanowska MK. Control of cardiovascular risk factors among adult cancer survivors: a population-based survey. Cancer Causes Control. 2010;21(11):1867–1874.
   Web of Science ®Google Scholar
• Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7(2):253–261.
   PubMed Web of Science ®Google Scholar
• Burnett D, Kluding P, Porter C, Fabian C, Klemp J. Cardiorespiratory fitness in breast cancer survivors. Springerplus. 2013;2(1):68.
   Google Scholar
• Cantarero-Villanueva I, Galiano-Castillo N, Fernandez-Lao C, et al. The influence of body mass index on survival in breast cancer patients. Clin Breast Cancer. 2015;15(2):e117–e123.
   PubMed Web of Science ®Google Scholar
• Caro-Morán E, Fernández-Lao C, Galiano-Castillo N, Cantarero-Villanueva I, Arroyo-Morales M, Díaz-Rodríguez L. Heart rate variability in breast cancer survivors after the first year of treatments: a case-controlled study. Biol Res Nurs. 2016;18(1):43–49.
   Web of Science ®Google Scholar
• de Azambuja E, Ameye L, Diaz M, et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer. 2015;51(17):2517–2524.
   PubMed Web of Science ®Google Scholar
• Gallicchio L, Calhoun C, Helzlsouer K. Effect of aromatase inhibitor therapy on the cardiovascular health of black and white breast cancer patients. Clin Breast Cancer. 2016;16(3):e23–e31.
   Web of Science ®Google Scholar
• Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart. 2010;96(9):701–707.
   PubMed Web of Science ®Google Scholar
• Inanc MT, Karadavut S, Aytekin M, et al. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients. Int J Cardiol. 2016;218:246–251.
   Web of Science ®Google Scholar
• Jones LW, Haykowsky M, Peddle CJ, et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007;16(5):1026–1031.
   PubMed Web of Science ®Google Scholar
• Murtagh G, Lyons T, O’Connell E, et al. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat. 2016;156(3):501–506.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. How does smoking affect the heart and blood vessels? Maryland: National Institute of Health. [updated June 22, 2016]. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/smo/. Accessed July 22, 2016.
   Google Scholar
• National Heart, Lung, and Blood Institute. What are the risk factors for heart disease? Maryland: National Institute of Health. [updated July 10, 2014]. Available from: http://www.nhlbi.nih.gov/health/educational/hearttruth/lower-risk/risk-factors.htm. Accessed July 22, 2016.
   Google Scholar
• World Heart Federation. Family history. Available from: http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/family-history/. Accessed July 22, 2016.
   Google Scholar
• National Coalition for Cancer Survivorship. NCCS: Our Mission. Available from: http://www.canceradvocacy.org/about-us/our-mission/. Accessed July 22, 2016.
   Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Implementing Cancer Survivorship Care Planning. Washington, DC: The National Academies Press; 2007.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman, DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar